# Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

> **NCT05287984** · PHASE2 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 63 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Newly Diagnosed

## Interventions

- **DRUG:** Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
- **DRUG:** Zanubrutinib, bendamustine, rituximab

## Key facts

- **NCT ID:** NCT05287984
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-22
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-11-29
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05287984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05287984, "Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05287984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*